IVIg Trial
Learn more about Octapharma’s Phase 3 trial of IVIg in PANS, currently under way.
Did your child recently start showing Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS/PANDAS) symptoms?
Consider enrolling them in the ProPANS IVIg study.
This study will look at how well an IVIg study drug* may work for children 6 to 17 years of age who have PANS/PANDAS. Other study requirements apply.
* This drug has been FDA approved to address other conditions, but it is not FDA approved for the use of addressing PANS symptoms in children.
Study participants receive at no cost:
- Access to a new IVIg study drug that may help with managing PANS
- All participants will receive the study drug and placebo (no active ingredients). Participants will be randomly assigned to receive the study drug in either the first or second half of the study
- Study support and study-related monitoring by a healthcare team
- Help with study-related travel expenses, including reimbursements for lodging, transportation, and meals
- Education about PANS/PANDAS
- The opportunity to help advance PANS research
The ProPANS study will be conducted at a select number of medical universities and institutions under the direction of Octapharma AG.
For more information or to learn if your child may qualify, please contact:
Email: PANStrial@octapharma.com
Phone: 888 885 4598
A Free Webinar and Q&A to Review Octapharma’s Superiority Study to Compare the Effect of IVIg (Panzyga) Versus Placebo in Patients with PANS/PANDAS
Neuroimmune Foundation’s hosts Huub Kreuwel, PhD and Snedhal Udavat of Octapharma USA Inc. in a one hour webinar recording on their phase III trial of IVIg in patients with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS).
Huub Kreuwel PhD is the VP of scientific and medical affairs of Octapharma USA. He oversees a team of medical doctors, nurses and pharmacists to provide medical education to patients and health care practitioners. He received his PhD in immunology from the Free University of Amsterdam in collaboration with The Scripps Research Institute, La Jolla. He has published research in Immunity, Journal of Immunology, Immunotherapy and Current Opinion in Immunology.
Snehal Udavat is the Associate Director of Clinical operations at Octapharma USA. He oversees a team of clinical researchers and manages clinical trials within the Immunology and Critical Care Therapeutic Areas. He has been working with Octapharma for the past 10 years and has been in the industry for the past 15 years.
Huub Kreuwel, PhD
Snehal Udavat, Study Manager
